Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
54.8M
-
Number of holders
-
121
-
Total 13F shares, excl. options
-
26M
-
Shares change
-
+3.8M
-
Total reported value, excl. options
-
$559M
-
Value change
-
+$83.4M
-
Put/Call ratio
-
0.84
-
Number of buys
-
60
-
Number of sells
-
-47
-
Price
-
$21.50
Significant Holders of Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) as of Q2 2019
165 filings reported holding CARA - Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2019.
Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) has 121 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26M shares
of 54.8M outstanding shares and own 47.49% of the company stock.
Largest 10 shareholders include RHO CAPITAL PARTNERS INC (3.27M shares), BlackRock Inc. (2.86M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.8M shares), FIRST MANHATTAN CO (1.94M shares), STATE STREET CORP (1.83M shares), VANGUARD GROUP INC (1.78M shares), Chescapmanager LLC (1.1M shares), ETF MANAGERS GROUP, LLC (953K shares), FARALLON CAPITAL MANAGEMENT LLC (951K shares), and DISCIPLINED GROWTH INVESTORS INC /MN (838K shares).
This table shows the top 121 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.